Impact of sodium-glucose cotransporter-2 (SLGT2) inhibitors treatment initiation on the reduction of atrial and ventricular arrhythmias in patients with implanted cardiac devices.

Back

ESC Professional Premium Access

Impact of sodium-glucose cotransporter-2 (SLGT2) inhibitors treatment initiation on the reduction of atrial and ventricular arrhythmias in patients with implanted cardiac devices.

Session: Update on EP studies, anti-arrhythmic drugs, and ablation techniques

Topic: Antiarrhythmic Drug Treatment

Speaker: Doctor E. Sanchez Munoz (Leon, ES)

Event: ESC Congress 2023

Congress Presentation

Add to my library

About the speaker

Doctor Enrique Sanchez Munoz

Hospital of Leon, Leon (Spain)

1 presentation

0 follower

5 more presentations in this session

High-power short-duration ablation of the atrioventricular node

Speaker: Doctor M. Alsaiqali (Sioux Falls, US)

Risk of stiff left atrial syndrome following pulse-field-based ablation of atrial fibrillation in patients with pulmonary hypertension at baseline

Speaker: Doctor S. Mohanty (Austin, US)

A comparison of general anesthesia versus monitored anesthesia care during catheter ablation for ventricular tachycardia

Speaker: Ms T. Woelber (Rochester, US)

Atypical flutter: effectiveness of a systematic strategy based on comprehensive high-density map analysis

Speaker: Doctor J. Brito (Lisbon, PT)

Risk of complications in patients undergoing pulmonary vein antrum isolation: a single centre experience

Speaker: Doctor M. Pirbaglou (Newmarket, CA)

Access the full session

Update on EP studies, anti-arrhythmic drugs, and ablation techniques

Speakers: Doctor E. Sanchez Munoz, Doctor M. Alsaiqali, Doctor S. Mohanty, Ms T. Woelber, Doctor J. Brito...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources